First Adult Seizure Medication

  • Author: Eissa Ibrahim AlEissa, MBBS, MD; Chief Editor: Selim R Benbadis, MD   more...
 
Updated: Jun 8, 2011
 

Medication Summary

The chosen antiepileptic drug should have high efficacy, long-term safety, good tolerability, and low interaction potential, and the agent should allow a good quality of life, especially because half of all patients never have another seizure without treatment.[7] These agents prevent seizure recurrence and terminate clinical and electrical seizure activity.[42]

The accepted principle is that one should begin with monotherapy. All newer (second-generation) agents are acceptable choices and are likely just as effective as older agents. An American Academy of Neurology (AAN) evidence-based guideline recommended lamotrigine, oxcarbazepine, topiramate, and gabapentin as appropriate for initial monotherapy; however, this guideline did not include newer antiepileptic drugs, such as levetiracetam and pregabalin.

Selected Anticonvulsant Trial Results

In an early report, phenytoin, carbamazepine, valproate, and phenobarbital were equally effective in treating newly diagnosed epilepsy; however, phenobarbital had more adverse effects.[43] Other authors agree that barbiturates should be avoided because of neurotoxic and cognitive side effects.[7]

SANAD study results

The Standard and New Antiepileptic Drugs (SANAD) study reported that lamotrigine was significantly better in terms of time to treatment failure than the current standard treatment, carbamazepine, and the newer drugs gabapentin and topiramate for treatment of partial seizures.[44] (The study compared carbamazepine, gabapentin, lamotrigine, oxcarbazepine, and topiramate.) For time to 12-month remission from seizures, carbamazepine was not significantly advantageous compared with lamotrigine.[44] Lamotrigine also has the lowest incidence of treatment failure and has better outcome than all drugs except oxcarbazepine.

The same SANAD study compared valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy seizures, and found that valproate is the drug of choice and is better tolerated than topiramate.[45]

Epilepsy monotherapy trial results

Another study compared 8 antiepileptic drugs used in 20 randomized trials and reported that in patients with partial seizures, the results favored carbamazepine, oxcarbazepine, and lamotrigine.[46] For generalized tonic-clonic seizures, the results favored valproate and phenytoin.[46]

NEAD study results

Regarding sodium valproate, the Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) Study Group recommended that sodium valproate not be used as a first-line drug in the treatment of epilepsy for women of child-bearing age because of its side effects.[47]

Anticonvulsant Safety and Tolerability

Although phenytoin, carbamazepine, valproate, and phenobarbital were initially reported as equally effective in treating newly diagnosed epilepsy, phenobarbital had more adverse effects.[43] In general, barbiturates should be avoided because of neurotoxic and cognitive side effects.[7]

Overall, the newer antiepileptic drugs appear safer and better tolerated; however, they have not been used for as long or in as many patients as the older drugs. None of the common side effects of the older drugs (eg, gum hyperplasia, neuropathy) have been identified; however, ruling out potential new problems with long-term use of the newer antiepileptic drugs is difficult. Head-to-head studies have demonstrated favorable side effect profiles for gabapentin when compared with carbamazepine, and for oxcarbazepine and lamotrigine when compared with both phenytoin and carbamazepine.

All newer antiepileptic drugs, although "officially" approved as adjunctive therapy, are acceptable options for monotherapy (off-label use).

Privitera et al found topiramate 100 mg/d is as effective as therapeutic doses of carbamazepine and sodium valproate and has the fewest discontinuations due to adverse events.[48]

Next

Anticonvulsants

Class Summary

Anticonvulsant agents, including lamotrigine, gabapentin, oxcarbazepine, topiramate, and valproic acid, are commonly used for the treatment of seizures. Initial treatment includes monotherapy. Newer agents are acceptable choices and are likely just as effective as older agents.

View full drug information

Lamotrigine (Lamictal, Lamictal XR, Lamictal ODT)

 

Lamotrigine is a triazine derivative that inhibits the release of glutamate and voltage-sensitive sodium channels, leading to stabilization of the neuronal membrane. Lamotrigine is indicated for both adjunctive treatment and monotherapy for epilepsy.

View full drug information

Oxcarbazepine (Trileptal)

 

The pharmacological activity of oxcarbazepine is primarily by the 10-monohydroxy metabolite (MHD) of oxcarbazepine. It may block voltage-sensitive sodium channels, inhibit repetitive neuronal firing, and impair synaptic impulse propagation. This drug's anticonvulsant effect may also occur by affecting potassium conductance and high-voltage activated calcium channels.

View full drug information

Carbamazepine (Tegretol, Tegretol XR, Epitol, Carbatrol)

 

Carbamazepine has anticonvulsant actions that may involve depressing activity in the nucleus ventralis anterior of the thalamus, resulting in a reduction of polysynaptic responses and blocking posttetanic potentiation. It reduces sustained high-frequency repetitive neural firing. It is indicated for partial seizures, generalized tonic-clonic seizures, and mixed seizures.

View full drug information

Topiramate (Topamax, Topiragen, Topamax Sprinkles)

 

Topiramate is a sulfamate-substituted monosaccharide with a broad spectrum of antiepileptic activity that may have a state-dependent sodium channel blocking action, potentiation of the inhibitory activity of the neurotransmitter gamma-aminobutyrate (GABA), and, possibly, blocking of glutamate activity. Topiramate is indicated for both adjunctive treatment and monotherapy for epilepsy.

View full drug information

Gabapentin (Neurontin)

 

Gabapentin is a membrane stabilizer, a structural analogue of the inhibitory neurotransmitter GABA, which, paradoxically, is thought not to exert an effect on GABA receptors. It appears to exert action via the alpha(2)delta1 and alpha(2)delta2 auxiliary subunits of voltage-gaited calcium channels.

It is used to manage pain and provide sedation in neuropathic pain. Titration to effect can take place over several days (300 mg on day 1, 300 mg bid on day 2, and 300 mg tid on day 3).

View full drug information

Valproic acid (Depakote, Depakene, Depacon, Depakote ER, Stavzor)

 

Valproic acid is chemically unrelated to other drugs used to treat seizure disorders. Although its mechanism of action is not established, the activity of valproic acid may be related to increased brain levels of GABA or enhanced GABA action. This agent may also potentiate postsynaptic GABA responses, affect potassium channels, or have a direct membrane-stabilizing effect.

View full drug information

Phenytoin (Dilantin, Phenytek, Dilantin Infatabs)

 

Phenytoin may act in the motor cortex, where it may inhibit the spread of seizure activity. The activity of brain stem centers responsible for the tonic phase of grand mal seizures may also be inhibited. The dose administered should be individualized.

Previous
 
Contributor Information and Disclosures
Author

Eissa Ibrahim AlEissa, MBBS, MD  Consultant Neurologist, Prince Salman Hospital, Saudi Arabia

Eissa Ibrahim AlEissa, MBBS, MD is a member of the following medical societies: American Academy of Neurology and American Epilepsy Society

Disclosure: Nothing to disclose.

Coauthor(s)

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting

Specialty Editor Board

Anthony M Murro, MD  Professor, Laboratory Director, Department of Neurology, Medical College of Georgia

Anthony M Murro, MD is a member of the following medical societies: American Academy of Neurology and American Epilepsy Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Jose E Cavazos, MD, PhD, FAAN  Associate Professor with Tenure, Departments of Neurology, Pharmacology, and Physiology, Program Director of the Clinical Neurophysiology Fellowship, University of Texas School of Medicine at San Antonio; Co-Director, South Texas Comprehensive Epilepsy Center, University Hospital System; Director of the San Antonio Veterans Affairs Epilepsy Center of Excellence and Neurodiagnostic Centers, Audie L Murphy Veterans Affairs Medical Center

Jose E Cavazos, MD, PhD, FAAN is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, American Epilepsy Society, and American Neurological Association

Disclosure: GXC Global, Inc. Intellectual property rights Medical Director - company is to develop a seizure detecting device. No conflict with any of the eMedicine articles that I wrote or edited.

Chief Editor

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting

Acknowledgments

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author William J Nowack, MD, to the development and writing of the source article.

References

  1. Scheepers B, Clough P, Pickles C. The misdiagnosis of epilepsy: findings of a population study. Seizure. Oct 1998;7(5):403-6. [Medline].

  2. Benbadis SR. Differential diagnosis of epilepsy. Continuum Lifelong Learn Neurol. 2007;13:48-70.

  3. [Guideline] Engel J Jr. Report of the ILAE classification core group. Epilepsia. Sep 2006;47(9):1558-68. [Medline].

  4. [Guideline] Commission on Epidemiology and Prognosis, International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. Epilepsia. 1993;34(4):592-6. [Medline].

  5. [Guideline] Commission on Epidemiology and Prognosis, International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989;30(4):389-99. [Medline].

  6. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. Apr 2010;51(4):676-85. [Medline]. [Full Text].

  7. Pohlmann-Eden B, Beghi E, Camfield C, Camfield P. The first seizure and its management in adults and children. BMJ. Feb 11 2006;332(7537):339-42. [Medline].

  8. Musicco M, Beghi E, Bordo B. Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. First Seizure Trial Group (FIR.S.T. Group). Neurology. Mar 1993;43(3 pt 1):478-83. [Medline].

  9. Annegers JF, Shirts SB, Hauser WA, Kurland LT. Risk of recurrence after an initial unprovoked seizure. Epilepsia. Jan-Feb 1986;27(1):43-50. [Medline].

  10. Hauser WA, Rich SS, Annegers JF, Anderson VE. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology. Aug 1990;40(8):1163-70. [Medline].

  11. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology. Jul 1991;41(7):965-72. [Medline].

  12. Labovitz DL, Hauser WA, Sacco RL. Prevalence and predictors of early seizure and status epilepticus after first stroke. Neurology. Jul 24 2001;57(2):200-6. [Medline].

  13. Hopkins A, Garman A, Clarke C. The first seizure in adult life. Value of clinical features, electroencephalography, and computerised tomographic scanning in prediction of seizure recurrence. Lancet. Apr 2 1988;1(8588):721-6. [Medline].

  14. Bora I, Seckin B, Zarifoglu M, Turan F, Sadikoglu S, Ogul E. Risk of recurrence after first unprovoked tonic-clonic seizure in adults. J Neurol. Feb 1995;242(3):157-63. [Medline].

  15. Martinovic Z, Jovic N. Seizure recurrence after a first generalized tonic-clonic seizure, in children, adolescents and young adults. Seizure. Dec 1997;6(6):461-5. [Medline].

  16. Camfield PR, Camfield CS, Dooley JM, Tibbles JA, Fung T, Garner B. Epilepsy after a first unprovoked seizure in childhood. Neurology. Nov 1985;35(11):1657-60. [Medline].

  17. van Donselaar CA, Schimsheimer RJ, Geerts AT, Declerck AC. Value of the electroencephalogram in adult patients with untreated idiopathic first seizures. Arch Neurol. Mar 1992;49(3):231-7. [Medline].

  18. Beghi E, Berg AT, Hauser WA. Treatment of Single Seizures. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Lippincott-Raven; 1997:1287-94.

  19. Hesdorffer DC, Logroscino G, Benn EK, Katri N, Cascino G, Hauser WA. Estimating risk for developing epilepsy: a population-based study in Rochester, Minnesota. Neurology. Jan 4 2011;76(1):23-7. [Medline]. [Full Text].

  20. Hauser WA, Beghi E. First seizure definitions and worldwide incidence and mortality. Epilepsia. 2008;49 Suppl 1:8-12. [Medline].

  21. Kotsopoulos IA, van Merode T, Kessels FG, de Krom MC, Knottnerus JA. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia. Nov 2002;43(11):1402-9. [Medline].

  22. Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorffer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol. Oct 2005;4(10):627-34. [Medline].

  23. Musicco M, Beghi E, Solari A, Viani F. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group). Neurology. Oct 1997;49(4):991-8. [Medline].

  24. King MA, Newton MR, Jackson GD, et al. Epileptology of the first-seizure presentation: a clinical, electroencephalographic, and magnetic resonance imaging study of 300 consecutive patients. Lancet. Sep 26 1998;352(9133):1007-11. [Medline].

  25. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. May-Jun 1993;34(3):453-68. [Medline].

  26. Hesdorffer DC, Benn EK, Cascino GD, Hauser WA. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia. May 2009;50(5):1102-8. [Medline].

  27. Benbadis SR. The differential diagnosis of epilepsy: A critical review. Epilepsy Behav. 2009;15:15-21.

  28. Sheldon R, Rose S, Ritchie D, et al. Historical criteria that distinguish syncope from seizures. J Am Coll Cardiol. Jul 3 2002;40(1):142-8. [Medline].

  29. Moore-Sledge CM. Evaluation and management of first seizures in adults. Am Fam Physician. Sep 15 1997;56(4):1113-20. [Medline].

  30. Benbadis SR, Wolgamuth BR, Goren H, Brener S, Fouad-Tarazi F. Value of tongue biting in the diagnosis of seizures. Arch Intern Med. Nov 27 1995;155(21):2346-9. [Medline].

  31. Benbadis SR. Provocative techniques should be used for the diagnosis of psychogenic nonepileptic seizures. Arch Neurol. Dec 2001;58(12):2063-5. [Medline].

  32. Benbadis SR. Errors in EEGs and the misdiagnosis of epilepsy: importance, causes, consequences, and proposed remedies. Epilepsy Behav. Nov 2007;11(3):257-62. [Medline].

  33. Nowack WJ. Epilepsy: a costly misdiagnosis. Clinical Electroencephalogr. 1997;28(4):225-228. [Medline].

  34. Zaidi A, Clough P, Cooper P, Scheepers B, Fitzpatrick AP. Misdiagnosis of epilepsy: many seizure-like attacks have a cardiovascular cause. J Am Coll Cardiol. Jul 2000;36(1):181-4. [Medline].

  35. Tardy B, Lafond P, Convers P, et al. Adult first generalized seizure: etiology, biological tests, EEG, CT scan, in an ED. Am J Emerg Med. Jan 1995;13(1):1-5. [Medline].

  36. Chadwick D, Smith D. Epileptology of the first-seizure presentation. Lancet. Dec 5 1998;352(9143):1855; author reply 1856. [Medline].

  37. Schreiner A, Pohlmann-Eden B. Value of the early electroencephalogram after a first unprovoked seizure. Clin Electroencephalogr. Jul 2003;34(3):140-4. [Medline].

  38. Benbadis SR, Lin K. Errors in EEG interpretation and misdiagnosis of epilepsy. Which EEG patterns are overread?. Eur Neurol. 2008;59(5):267-71. [Medline].

  39. Benbadis SR, Tatum WO. Overintepretation of EEGs and misdiagnosis of epilepsy. J Clin Neurophysiol. Feb 2003;20(1):42-4. [Medline].

  40. Simpson CS, Barlow MA, Krahn AD, et al. Recurrent seizure diagnosed by the insertable loop recorder. J Interv Card Electrophysiol. Oct 2000;4(3):475-9. [Medline].

  41. Chandra B. First seizure in adults: to treat or not to treat. Clin Neurol Neurosurg. 1992;94 suppl:S61-3. [Medline].

  42. Stein MA, Kanner AM. Management of newly diagnosed epilepsy: a practical guide to monotherapy. Drugs. 2009;69(2):199-222. [Medline].

  43. Heller AJ, Chesterman P, Elwes RD, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry. Jan 1995;58(1):44-50. [Medline].

  44. Marson AG, Al-Kharusi AM, Alwaidh M, et al, for the SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. Mar 24 2007;369(9566):1000-15. [Medline].

  45. Marson AG, Al-Kharusi AM, Alwaidh M, et al, for the SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. Mar 24 2007;369(9566):1016-26. [Medline].

  46. Tudur Smith C, Marson AG, Chadwick DW, Williamson PR. Multiple treatment comparisons in epilepsy monotherapy trials. Trials. Nov 5 2007;8:34. [Medline]. [Full Text].

  47. Meador KJ, Baker GA, Browning N, et al for the NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. Apr 16 2009;360(16):1597-605. [Medline].

  48. Privitera MD, Brodie MJ, Mattson RH, et al, for the EPMN 105 Study Group. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. Mar 2003;107(3):165-75. [Medline].

 
Previous
Next
 
An electroencephalogram (EEG) recording of a temporal lobe seizure. The ictal EEG pattern is shown in the rectangular areas.
An electroencephalogram (EEG) recording from a patient with primary generalized epilepsy. A burst of bilateral spike and wave discharge is shown in the rectangular area.
An electroencephalogram (EEG) recording of a seizure from a subdural array in a patient evaluated for epilepsy surgery. The subdural electrodes record from the left anterior temporal (LAT), left middle temporal (LMT), and left posterior temporal (LPT) regions. The EEG seizure pattern is seen best in bipolar EEG channels LAT 3-4 and LMT 3-4 (rectangular areas).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.